{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:07:59Z","timestamp":1783033679300,"version":"3.54.6"},"reference-count":26,"publisher":"Cambridge University Press (CUP)","issue":"S2","license":[{"start":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T00:00:00Z","timestamp":1463011200000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Laryngol. Otol."],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. Recurrent cancers present some of the most challenging management issues in head and neck surgical and oncological practice. This is rendered even more complex by the poor evidence base to support management options, the substantial implications that treatments can have on the function and quality of life, and the difficult decision-making considerations for supportive care alone. This paper provides consensus recommendations on the management of recurrent head and neck cancer.<\/jats:p><jats:sec id=\"S002221511600061X_sec_a1\"><jats:title>Recommendations<\/jats:title><jats:p>\u2022 Consider baseline and serial scanning with computed tomography and\/or magnetic resonance (CT and\/or MR) to detect recurrence in high-risk patients. (R)<\/jats:p><jats:p>\u2022 Patients with head and neck cancer recurrence being considered for active curative treatment should undergo assessment by positron emission tomography combined with computed tomography (PET\u2013CT) scan. (R)<\/jats:p><jats:p>\u2022 Patients with recurrence should be assessed systematically by a team experienced in the range of management options available for recurrence including surgical salvage, re-irradiation, chemotherapy and palliative care. (R)<\/jats:p><jats:p>\u2022 Management of patients with laryngeal recurrence should include input from surgeons with experience in transoral surgery and partial laryngectomy for recurrence. (G)<\/jats:p><jats:p>\u2022 Expertise in transoral surgery and partial laryngectomy for recurrence should be concentrated to a few surgeons within each multidisciplinary teams. (G)<\/jats:p><jats:p>\u2022 Transoral or open partial laryngectomy should be offered as definitive treatment modality for highly-selected patients with recurrent laryngeal cancer. (R)<\/jats:p><jats:p>\u2022 Patients with OPC recurrence should have p16 human papilloma virus status assessed. (R)<\/jats:p><jats:p>\u2022 Patients with OPC recurrence should be considered for salvage surgical treatment by an experienced team, with reconstructive expertise input. (G)<\/jats:p><jats:p>\u2022 Transoral surgery appears to be an effective alternative to open surgery for the management of OPC recurrence in carefully selected patients. (R)<\/jats:p><jats:p>\u2022 Consider elective selective neck dissections in patients with recurrent primaries with N0 necks, especially in advanced cases. (R)<\/jats:p><jats:p>\u2022 Selective neck dissection (with preservation of nodal levels, especially level V, that are not involved by disease) in patients with nodal (N+) recurrence appears to be as effective as modified or radical neck dissections. (R)<\/jats:p><jats:p>\u2022 Use salivary bypass tubes following salvage laryngectomy. (R)<\/jats:p><jats:p>\u2022 Use interposition muscle-only pectoralis major or free flap for suture line reinforcement if performing primary closure following salvage laryngectomy. (R)<\/jats:p><jats:p>\u2022 Use inlaid pedicled or free flap to close wound if there is tension at the anastomosis following laryngectomy. (R)<\/jats:p><jats:p>\u2022 Perform secondary puncture in post chemoradiotherapy laryngectomy patients. (R)<\/jats:p><jats:p>\u2022 Triple therapy with platinum, cetuximab and 5-fluorouracil (5-FU) appears to provide the best outcomes for the management of patients with recurrence who have a good performance status and are fit to receive it. If not fit, then combinations of platinum and cetuximab or platinum and 5-FU may be considered. (R)<\/jats:p><jats:p>\u2022 Patients with non-resectable recurrent disease should be offered the opportunity to participate in phases I\u2013III clinical trials of new therapeutic agents. (R)<\/jats:p><jats:p>\u2022 Chemo re-irradiation appears to improve locoregional control, and may have some benefit for overall survival, at the risk of considerable acute and late toxicity. Benefit must be weighed carefully against risks, and patients must be counselled appropriately. (R)<\/jats:p><jats:p>\u2022 Target volumes should be kept tight and elective nodal irradiation should be avoided. (R)<\/jats:p><jats:p>\u2022 Best supportive care should be offered routinely as part of the management package of all patients with recurrent cancer even in the case of those who are being treated curatively. (R)<\/jats:p><\/jats:sec>","DOI":"10.1017\/s002221511600061x","type":"journal-article","created":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T10:37:06Z","timestamp":1463049426000},"page":"S181-S190","source":"Crossref","is-referenced-by-count":80,"title":["Recurrent head and neck cancer: United Kingdom National Multidisciplinary Guidelines"],"prefix":"10.1017","volume":"130","author":[{"given":"H","family":"Mehanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SK","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2016,5,12]]},"reference":[{"key":"S002221511600061X_ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071028"},{"key":"S002221511600061X_ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.1937"},{"key":"S002221511600061X_ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802656"},{"key":"S002221511600061X_ref17","doi-asserted-by":"publisher","DOI":"10.1017\/S0022215114000425"},{"key":"S002221511600061X_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2013.12.002"},{"key":"S002221511600061X_ref25","doi-asserted-by":"publisher","DOI":"10.1002\/hed.20697"},{"key":"S002221511600061X_ref7","doi-asserted-by":"publisher","DOI":"10.1002\/lary.23941"},{"key":"S002221511600061X_ref14","doi-asserted-by":"publisher","DOI":"10.1080\/00016480600818062"},{"key":"S002221511600061X_ref10","doi-asserted-by":"publisher","DOI":"10.1002\/hed.20009"},{"key":"S002221511600061X_ref8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24595"},{"key":"S002221511600061X_ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2011.06.025"},{"key":"S002221511600061X_ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-4486.2008.01738.x"},{"key":"S002221511600061X_ref22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.4646"},{"key":"S002221511600061X_ref18","doi-asserted-by":"publisher","DOI":"10.1002\/hed.20987"},{"key":"S002221511600061X_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.anl.2009.07.004"},{"key":"S002221511600061X_ref1","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.129.1.44"},{"key":"S002221511600061X_ref19","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.131.11.965"},{"key":"S002221511600061X_ref16","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.132.1.67"},{"key":"S002221511600061X_ref20","doi-asserted-by":"publisher","DOI":"10.1002\/hed.20489"},{"key":"S002221511600061X_ref24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.0691"},{"key":"S002221511600061X_ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2013.3866"},{"key":"S002221511600061X_ref13","doi-asserted-by":"publisher","DOI":"10.1002\/lary.24619"},{"key":"S002221511600061X_ref12","doi-asserted-by":"publisher","DOI":"10.1002\/hed.23291"},{"key":"S002221511600061X_ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-1893-y"},{"key":"S002221511600061X_ref3","volume-title":"Management of Recurrence in Head and Neck Cancer","author":"Mehanna","year":"2012"},{"key":"S002221511600061X_ref2","doi-asserted-by":"crossref","unstructured":"Jayaram SC , Muzaffar SJ , Ahmed I , Dhanda J , Paleri V , Mehanna HM. The efficacy, outcomes and complication rates of different surgical and nonsurgical treatment modalities for recurrent\/residual oropharyngeal carcinoma: a systematic review and meta-analysis. Head Neck 2016 [in press]","DOI":"10.1002\/hed.24531"}],"container-title":["The Journal of Laryngology &amp; Otology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S002221511600061X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T19:39:00Z","timestamp":1555702740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S002221511600061X\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":26,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S002221511600061X"],"URL":"https:\/\/doi.org\/10.1017\/s002221511600061x","relation":{},"ISSN":["0022-2151","1748-5460"],"issn-type":[{"value":"0022-2151","type":"print"},{"value":"1748-5460","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}